Section: Microbiology

Original Research Article

ARTIFICIAL INTELLIGENCE IN MICROBIOLOGY: ADVANCES, CHALLENGES, AND FUTURE DIRECTIONS FOR GLOBAL HEALTH

Mayuri K.S[1], Adithi Y Chenji[2]

[1]*Associate Professor, Department of Microbiology, Sir Seewoosagur Medical College Belle Rive Mauritius*
[2]*Final year student, MSc Life science, Mount Carmel College Autonomous, Bangalore, Karnataka, India*

Received : *17/04/2026*
Received in revised form : *10/06/2026*
Accepted : *28/06/2026*

Corresponding Author:
Dr. Mayuri.K.S,
Associate Professor, Department of Microbiology, Sir Seewoosagur Medical college Belle Rive Mauritius.
Email: mayuri.bekal@gmail.com

DOI: 10.70034/ijmedph.2026.3.68

Source of Support: Nil,
Conflict of Interest: None declared

Int J Med Pub Health
2026; 16 (3); 419-427

ABSTRACT

Artificial intelligence (AI), more specifically machine learning (ML) and deep learning (DL), is revolutionizing microbiology through the use of speeded-up microbial identification, antimicrobial resistance (AMR) prediction, drug discovery, and epidemiological surveillance. Culture-based assays, microscopy, and 16S rRNA sequencing are traditional techniques that are still necessary but hampered by time, scalability, and ability to differentiate closely related taxa. AI-based methods, such as convolutional neural networks (CNN), random forests, and transformer architectures, now facilitate high-throughput, fast analysis of genomic, proteomic, metabolomic, and imaging data, outperforming traditional diagnostics in sensitivity and reproducibility. In clinical microbiology, integration of AI with systems like MALDI-TOF MS and digital pathology platforms enables quicker pathogen identification, personalized therapy, and infection control. In addition to diagnostics, AI enables microbiome profiling, expediting the identification of new antimicrobials (e.g., Halicin, Abaucin), and optimizing vaccine design via epitope prediction and antigen prioritization. Predictive systems empowered by AI also improve outbreak detection, point-of-care testing, and sepsis treatment, with expanding uses in environmental microbiology and food safety. Despite this, issues remain with data quality, algorithmic bias, interpretability, regulation, and clinic adoption. Future directions highlight multi-omics integration, personalized medicine, laboratory automation, synthetic biology, and AI-powered global health surveillance. By and large, AI will complement microbiological research and practice to develop precision diagnosis, optimal therapeutics, and enhanced public health preparedness.

INTRODUCTION

Microbiology, the science of microorganisms like bacteria, viruses, fungi, and protozoa, is a fast-changing field with far-reaching consequences for human health, agriculture, and biotechnology. Classical microbiological methods, such as culture-based assays and polymerase chain reaction (PCR), have been the mainstay of microbial research and diagnostics. These methods are, however, time-consuming, labor-intensive, and limited in their ability to handle the huge and complex biological data produced by contemporary biological research.[1]

Recent developments in artificial intelligence (AI), specifically machine learning (ML) and deep learning (DL), have brought revolutionary potential to microbiology. AI algorithms are particularly well-suited to process high-dimensional genomic, proteomic, and metabolomic data and thus facilitate swift microbial identification, functional description, and predictive modelling.[2,3] This ability is particularly important in drug discovery, where AI-based methods are speeding the quest for new antimicrobial agents to treat multidrug-resistant infections, an expanding world health problem.[4,5]

In clinical microbiology, the combination of AI with emerging technologies like MALDI-TOF MS has improved diagnostic speed and accuracy, providing cost-efficient and scalable solutions for microbial identification and antimicrobial resistance profiling.[6,7] In addition to diagnostics, AI facilitates infection prevention and control by processing large-scale health data, enabling outbreak detection, epidemiological surveillance, and risk stratification.[8,9] Its use in the treatment of infectious diseases and sepsis further highlights its potential to enhance prognosis, inform personalized treatments, and enhance healthcare delivery.[10,11]

This review presents an exhaustive overview of the uses of AI in microbiology, including its application in research, diagnostics, and public health. Besides, it discusses challenges in adopting AI and looks into ways forward in incorporating these technologies into microbial sciences.

Table 1: Summary of AI applications in microbiology

Domain	AI Tool	Application	Outcome
Microbial Identification	CNNs, SVMs	Automated microscopy, colony recognition	Faster, more accurate than manual
AMR Prediction	DeepARG, AMRPlusPlus	WGS-based resistance prediction	Early, personalized antibiotic choice
Microbiome Analysis	Random Forest, MetaPhlAn 4	Disease prediction, ecology	Species-level resolution, host–microbe insights
Drug Discovery	Deep learning models	Screening millions of molecules	Novel antibiotics (e.g., Halicin, Abaucin)
Vaccine Design	Vaxign-ML, DL epitope predictors	Antigen/epitope selection	Accelerated vaccine development
Epidemiology	RNNs, ANN, ML	Outbreak prediction, surveillance	Early warning, real-time monitoring

Fundamentals of AI in Microbiology

Machine Learning (ML): Machine learning, a fundamental subdiscipline of artificial intelligence (AI), is transforming microbiology by allowing fast processing of large and intricate datasets. It has been used in various fields ranging from microbial classification to the forecasting of antimicrobial resistance (AMR). For instance, support vector machine (SVM) models have been able to predict both known and new AMR genes within Mycobacterium tuberculosis using datasets containing over 1500 genomes.[12] Overview of the primary uses of ML in microbiology is presented in [Figure 1].

Basics of Machine Learning: In essence, machine learning enables algorithms to learn patterns in data and make predictions without the need for explicit programming with rules. In microbiology, this ability has opened new areas of study in microbial genomics, proteomics, and metabolomics, as well as enhancing knowledge of host–pathogen interactions and disease mechanisms.[13]

Supervised Learning: Supervised learning depends on algorithms trained with labeled data where both the input variables and the resultant outcomes are known. The technique has been most successful for antibiotic resistance prediction, identification of virulence determinants, and microbial taxon classification.[14,15] For example, adaptive boosting classifiers and random forest models have been successfully utilized to identify AMR in clinically relevant bacterial species.[16,17]

Unsupervised Learning: Unsupervised learning is applied to unlabeled data to reveal hidden patterns or relationships that are not directly apparent. This is particularly useful in microbiome studies, where community complexity and ecological richness make pre-existing labels infeasible. Methods like clustering and dimensionality reduction assist in discovering microbial niches, identifying rare organisms, and correlating microbial composition with host health or disease.[18–20]

Deep Learning (DL): Deep learning, a specialized area of ML, employs multi-layered neural networks to analyze extremely complex data. Unlike conventional ML, DL models can automatically derive hierarchical features from raw data, requiring less preprocessing. In microbiology, deep learning has been effectively utilized for bacterial classification using images, genome annotation, predicting antimicrobial resistance, and metagenomic profiling.[21,22] Convolutional neural networks (CNNs) are utilized in the examination of microscopy images, while recurrent neural networks (RNNs) and transformer-based models are being used more frequently for genomic and transcriptomic information.[23] DL has been more recently utilized in metagenomics, enabling swift and accurate profiling of microbial communities from both environmental and clinical samples.[24]



Figure 1: Depicts a standard machine learning process in microbiology. Initially, the features including genomic sequences, transcriptomic profiles, proteomic markers, and phenotypic characteristics (morphology or motility) are gathered. They are paired with related outcomes, including resistance phenotype or clinical status, to train the predictive models. Through training, the algorithm learns the most informative features, tunes parameters, and constructs a prediction framework. After being validated, the model can be used to predict new, never-before-seen samples to make inferences about outcomes like antimicrobial resistance, pathogenicity, or shifts in microbial communities. The workflow illustrates how ML reduces raw biological data into actionable information for diagnostics, surveillance, and drug development.

AI in Microbial Identification and Classification

Traditional vs. AI-Based Microbial Identification: Traditional microbial identification has traditionally depended on phenotypic and genotypic techniques like Gram staining, biochemical tests, and 16S rRNA sequencing [Table 2]. Although these methods are useful, they are time-consuming, require significant effort, and are not very good at distinguishing between close relatives of the organism.[25] On the other hand, AI-based methods—especially machine learning (ML) and deep learning (DL) algorithms like convolutional neural networks (CNNs) and support vector machines (SVMs)—have shown impressive leaps forward in classification accuracy, processing speed, and scalability [Figure 2].[26]



Figure 2: Traditional microbial identification relies on staining, biochemical tests, and sequencing, which are slow and less precise. AI-based methods use imaging and machine learning to enable faster, scalable, and more accurate classification.

AI in Microscopy and Imaging: Artificial intelligence microscopy is revolutionizing microbial diagnosis by facilitating automated interpretation of images [Figure 3]. A proof-of-concept study in 2018 illustrated the use of CNNs for automated assessment of blood culture Gram stains with training on more than 100,000 crops of images, and it showed very high accuracy in distinguishing Gram-negative rods, Gram-positive cocci in clusters, and cocci in chains.[27] More contemporary developments have continued this work: DL models now facilitate high-throughput bacterial colony identification, morphological description, and immediate species recognition from digital slides, frequently with superior performance compared to manual interpretation.[28]

The combination of AI with chromogenic agar culture plate imaging has also improved detection of colonies. AI algorithms can enumerate and differentiate colonies in urine cultures with as much as 99.8% sensitivity and substantially shorter turnaround times (less than 5 hours for negative results and ~3.5 hours for positive results), providing similar performance to molecular diagnostics at a lower cost.[29] Similarly, AI-driven digital pathology platforms are increasingly applied in parasitology and hematology, including malaria diagnosis, where CNN-based computer-aided diagnosis (CADx) tools now outperform human slide readers in sensitivity and reproducibility.[30]

Figure 3: Overview of AI applications in microbiology.

Advancements in Clinical Diagnostics and Disease Detection: AI and ML applications are revolutionizing medical microbiology by enabling rapid, precise detection of pathogens in clinical and environmental samples. For example, deep learning frameworks have successfully been applied to fecal microscopy, achieving higher sensitivity than conventional parasitological methods in detecting protozoa and helminths.[31] Automated bacterial identification systems now analyze colony morphology, pigmentation, and growth dynamics from high-resolution images, supporting applications across medical, veterinary, and food microbiology [Figure 4].



Figure 4: AI integration into the clinical microbiology workflow. Patient samples undergo laboratory processing, followed by AI/ML-based feature extraction and data integration. Clinical decision support tools then guide personalized therapy, feeding back into improved patient outcomes.

AI in Antimicrobial Resistance (AMR) Prediction: Antimicrobial resistance (AMR) remains one of the greatest global health threats, with multidrug-resistant pathogens undermining treatment efficacy and patient outcomes. AI and ML provide powerful tools for early prediction of AMR, guiding targeted antibiotic use and reducing misuse.[32]

Genomic-Based AMR Prediction: AI models trained on whole-genome sequencing (WGS) data are increasingly employed to predict resistance phenotypes. Tools such as ARG-ANNOT and ResFinder laid the groundwork but more recent deep learning frameworks (e.g., DeepARG and AMRPlusPlus) integrate genomic, transcriptomic, and metagenomic datasets to achieve higher accuracy in detecting both known and novel resistance genes.[33] Notably, large-scale applications in Mycobacterium tuberculosis and Escherichia coli have demonstrated the ability of AI models to predict resistance patterns with clinical utility.

Table 2: Applications of AI in microbial identification and diagnostics

Application Area	Traditional Method	AI/ML Approach	Key Advantages	References
Bacterial identification	Gram staining, biochemical tests, 16S rRNA	CNNs, SVMs, deep learning classifiers	Faster, scalable, higher accuracy for closely related species	[25,26]
Microscopy & Imaging	Manual slide interpretation	CNNs for Gram stains; CADx for malaria diagnosis	Automated, reproducible, outperform human readers	[27–30]
Colony recognition	Visual/manual plate reading	AI applied to chromogenic agar plates	99.8% sensitivity; rapid reporting of negatives	[29]
Clinical diagnostics	Manual parasitology	DL models for fecal microscopy	Higher sensitivity; faster parasite detection	[31]
Digital pathology	Manual pathology slides	AI-based digital pathology platforms	High-throughput, scalable, cost-effective	[28,30]

Clinical Decision Support Systems: AI-enabled clinical decision support systems (CDSS) are being integrated into routine hospital workflows [Figure 5]. Platforms such as IBM Watson for Microbiology analyze patient records, microbial genomic data, and epidemiological trends to recommend personalized antimicrobial therapies. These systems support stewardship programs by reducing inappropriate prescribing, minimizing adverse outcomes, and helping clinicians combat the spread of multidrug-resistant organisms.[34]



Figure 5: AI-driven antimicrobial resistance (AMR) prediction: multi-omics data are processed through AI/ML models to predict resistance phenotypes, discover novel resistance genes, and provide clinical decision support for precision therapy.

AI in Microbiome Analysis

Gut Microbiome and Disease Prediction: Machine learning approaches such as random forests, gradient boosting, and neural networks are increasingly used to link gut microbial composition with host health outcomes. Early studies, including, demonstrated the feasibility of using microbiome data to predict conditions such as inflammatory bowel disease and type 2 diabetes.[35] More recently, large meta-analyses have reported consistent performance across multiple cohorts. For example, a study analyzing more than 4,400 samples achieved an average AUC of 0.72 for distinguishing Parkinson's disease cases, highlighting both the potential of these methods and the ongoing challenge of cross-cohort standardization.[36]

Metagenomic Sequencing and AI: AI methods enhance the analysis of metagenomic sequencing data by enabling rapid and accurate identification of microbial communities in complex samples. Updated pipelines such as MetaPhlAn 4 now integrate isolate genomes with metagenome-assembled genomes, greatly expanding coverage of novel taxa and providing species-level resolution.[37] Similarly, Kraken 2 employs k-mer–based classification that is both fast and memory-efficient, and its translated search mode improves detection of viral and other highly variable sequences. These advances make taxonomic and functional profiling more robust and scalable.

AI in Drug Discovery and Vaccine Development

AI for Antibiotic Discovery: Artificial intelligence has emerged as a powerful tool for identifying novel antimicrobial compounds. A landmark example is the discovery of Halicin, identified by screening over 100 million molecules with a deep learning model and later shown to possess broad Gram-negative activity. More recently, AI-guided screening led to the identification of abaucin, a narrow-spectrum antibiotic effective against Acinetobacter baumannii by disrupting lipoprotein trafficking via LolE; its efficacy was further validated in a mouse infection model. These cases illustrate how AI can uncover structurally distinct antimicrobial agents beyond traditional discovery pipelines.

AI in Vaccine Design: AI is also transforming vaccine development by accelerating antigen discovery and epitope prediction. Tools such as Vaxign-ML apply supervised learning to prioritize protective antigens and were among the approaches deployed during the early phases of COVID-19 vaccine design. More recent advances in deep learning and transfer learning have improved prediction of both B-cell and T-cell epitopes, as well as design of multivalent vaccines. Reviews published between 2021 and 2024 emphasize the growing role of AI not only in epitope selection but also in optimizing adjuvants, streamlining clinical trials, and even supporting vaccine distribution logistics.

AI in Epidemiological Surveillance

Outbreak Prediction: AI and ML models, including recurrent neural networks (RNNs), logistic regression (LR), and artificial neural networks (ANNs), have shown remarkable potential in predicting infectious disease outbreaks. By analyzing epidemiological data, these tools provide early warnings for conditions such as Ebola virus disease (EVD), enabling timely interventions.[38] Mobile-based applications, such as the Ebola Care app, have further demonstrated how ML-driven analyses of clinical symptoms and laboratory data can support treatment decisions in real time. Additionally, AI has been applied to non-traditional data sources, such as social media and internet searches, to detect outbreak signals earlier than conventional systems, thus strengthening real-time surveillance.[39]

Point-of-Care (POC) Diagnostics: AI-driven diagnostic tools are transforming POC testing, particularly in resource-limited settings. For example, ML algorithms applied to routine urinalysis can effectively distinguish positive and negative cases of sexually transmitted infections, such as trichomoniasis, with high accuracy.[40] This not only accelerates diagnosis but also reduces reliance on laboratory infrastructure.

Drug and Vaccine Discovery: AI and ML approaches have become invaluable in identifying novel therapeutics and vaccine candidates. Large-scale data mining from public repositories such as ChemDB has revealed promising antiviral compounds against pathogens like HIV.[41] Similarly, ML classifiers have facilitated in silico vaccine candidate selection for Apicomplexan pathogens, expediting vaccine development pipelines.

Antimicrobial Resistance (AMR) Surveillance: One of the most pressing global health challenges is antimicrobial resistance (AMR). AI has been employed to identify resistance mechanisms in pathogens such as Mycobacterium tuberculosis and HIV.[42] By analyzing genomic and phenotypic datasets, ML models provide predictive insights into resistance profiles, guiding clinicians toward effective treatment strategies and informing stewardship programs.

Microbiome and Microbial Ecology: AI methods, particularly random forest (RF) algorithms, contribute to microbial ecology by predicting interactions within microbial communities. These tools enhance our understanding of ecological networks and host–microbe interactions. Forensic microbiology has also benefited from ML approaches, with post-mortem microbiome analyses aiding both legal investigations and public health diagnostics.[43] Furthermore, dimensionality reduction techniques, such as the generalized linear model-based ordination method (gOMMS), have been developed to address the complexity of microbiome datasets, improving interpretability and predictive capacity.

AI in Foodborne Pathogen Detection: Spectroscopic methods such as Raman scattering, Fourier transform infrared (FTIR) spectroscopy, and hyperspectral imaging (HSI) have been integrated with AI for the rapid detection of foodborne pathogens.[44] HSI, in particular, is gaining prominence for its ability to capture both spatial and spectral features of bacterial contaminants, enabling early detection. Advances in hyperspectral microscopic imaging (HMI) now allow simultaneous acquisition of image and spectral information from living cells, offering unprecedented accuracy in pathogen identification.

AI in Clinical Microbiology and Sepsis Management: Automated systems such as the Automated Plate Assessment System (APAS) Independence and PhenoMatrix have streamlined culture-based diagnostics for urinary tract infections and MRSA detection.[45] In parallel, total laboratory automation (TLA) systems like Kiestra TLA and WASPLab exemplify AI's role in high-throughput microbiological workflows.[46]

AI also plays a pivotal role in sepsis management. Predictive models outperform traditional scoring systems by identifying patients at risk of sepsis earlier.[47] Incorporating big data and natural language processing into sepsis screening tools further improves diagnostic accuracy. Clinical studies confirm that AI-enhanced early warning systems reduce mortality rates, shorten hospital stays, and enable personalized treatment strategies.[48] However, additional validation is needed before large-scale clinical integration.

Infection Surveillance and Control: By deciphering intricate datasets from electronic health records (EHRs), artificial intelligence (AI) has transformed infection surveillance by tracking healthcare-associated infections (HAIs) and assessing preventive measures.[49] High accuracy in detecting tuberculosis has been shown when deep learning is applied to chest radiography.[50] Similarly, ML-based pathogen detection models and AI-enhanced microscopy support targeted antibiotic management and quick diagnostics.[51] AI has a lot of potential for infection prevention and control initiatives, despite the difficulties in locating high-quality datasets for model training.

AI in Antibiotic Discovery Against MRSA: The integration of AI and ML has accelerated the discovery of novel antibiotics targeting multidrug-resistant pathogens, such as MRSA. Using molecular descriptors generated by tools like RDKit, ML models are trained and validated to predict antibiotic activity.[52] Advanced methods such as deep learning and Monte Carlo tree search identify structural classes predictive of antibacterial efficacy.[53]

Importantly, computational predictions are validated experimentally, demonstrating a powerful synergy between AI-driven insights and laboratory research.[54]

Specific Antibiotics for Specific Bacteria: In precision medicine, ML models have been used to predict phenotypic resistance, such as polymyxin resistance in Klebsiella pneumoniae clonal group 258.[55] This highlights the potential of AI to guide targeted therapy, ensuring optimal patient outcomes.

Contact Tracing and AI: During the COVID-19 pandemic, AI-powered mobile applications facilitated large-scale contact tracing and infection monitoring. By analyzing mobility data and proximity records, these systems identified high-risk exposures and contributed to outbreak containment.[56]

Challenges and Ethical Considerations

Data Privacy and Bias: Artificial intelligence models of microbiology depend on big data, which poses important issues related to patient privacy, ownership of data, and adherence to ethical and legal standards like GDPR and HIPAA. Equally problematic is algorithmic bias, which can be caused by unbalanced or non-representative data, resulting in biased diagnostic results or unequal healthcare provision.[57] Strengthening privacy-preserving computational tools, like federated learning and differential privacy, in addition to open reporting of dataset description and restrictions, is needed to meet these challenges.

Interpretable and Transparent AI Models: One major impediment to clinical adoption is the "black-box" nature of deep learning systems, which erodes user trust. Explainable AI (XAI) methods are increasingly used to improve transparency and enable clinicians to see how predictions are made.[58] Creating interpretable models that seamlessly fit into existing microbiological workflows is an ongoing area of research, requiring technical innovation and clinician involvement.

Data Quality and Algorithmic Robustness: The robustness of AI models is reliant on the quality of training data, but microbiological datasets tend to be noisy, incomplete, or imbalanced. Low data quality can lead to a lack of reproducibility and generalizability. Current trends are on sophisticated data-cleaning pipelines, normalization methods, and augmentation strategies to counter these limitations.[59] Standardization of microbiological datasets and benchmarking protocols should be a top priority in future research to ensure laboratory consistency.

AI in Infection Prevention and Control (IPC): AI has the potential to contribute to infection prevention and control (IPC) through analysis of large amounts of data and the ability to conduct real-time surveillance. But its reliance on high-quality data and absence of standardized reference frameworks are potential drawbacks. More clinical studies and better AI developer-IPC expert collaboration are needed to increase robustness, clinical applicability, and sensitivity to nuances in healthcare data.[60]

Clinical Integration and Acceptance: Its restricted uptake among clinicians is a testament to its complexity and perceived incongruity with the traditional medical logic. Models that learn to interface well with healthcare environments of varying types, also apply medical sense, and continually update themselves will be needed to win clinician trust. Educational programs and cross-functional training play important roles in driving uptake and faith in AI systems.[61]

Digitalization of Diagnostic Processes: Digitalization of microbiological diagnostics poses challenges in managing data, such as collection, storage, quality control, and cybersecurity. With increased volumes of diagnostic data expanding exponentially, high-end analytics platforms and visualization software will be necessary for successful interpretation. Education of laboratory staff in digital and computational skills is also crucial to best optimize AI-based diagnostic pipelines.[62,63]

Generalization, Transferability, and Dynamic Systems: The models of AI usually do not generalize across microbial species or transfer across various clinical and environmental settings. In addition, the dynamic and fast-changing nature of microbial populations renders the creation of static predictive models challenging. Recent approaches like continual learning and adaptive algorithms are being explored for enhancing model adaptability.[64,65]

Security, Resources, and Human–AI Collaboration: Security issues related to the manipulation of sensitive microbiological information are still a prime concern, particularly with AI-based diagnostics. Besides, lack of resources, including limited availability of high-performance computing, can stand in the way of model training and implementation in settings where resources are scarce. Successful teaming with microbiologists and expert AI personnel is needed to overcome resistance, build trust, and make sure that models are technically robust and clinically significant.[66,67]

Ethical and Regulatory Dimensions: Training data bias, non-interpretable nature, and ambiguity regarding oversight regulations pose intricate ethical issues. Interdisciplinary cooperation between microbiologists, data scientists, ethicists, and policymakers is vital for developing equitable and responsible paradigms. Open reporting of model construction, datasets, and validation procedures will enhance reproducibility and accountability, bringing AI research in line with the anticipated ethical guidelines seen in microbiology and clinical sciences.[68,70]

Figure 5. Challenges and ethical considerations in applying AI to microbiology, including data privacy, bias, interpretability, data quality, clinical integration, regulatory oversight, resource limitations, and human–AI collaboration.

Future Directions: Future research on using artificial intelligence (AI) in microbiology must focus on a number of promising areas.

Personalized medicine is likely to be revolutionary. Through the incorporation of microbial profiles into clinical decision support, AI could customize therapeutic approaches to patients individually. Precision medicine strategies, based on machine learning, could optimize treatments by considering the individual's distinctive microbiota.

Mitigation of antimicrobial resistance (AMR) will be an ongoing priority. AI-based models can aid the discovery of new antimicrobial agents, forecast the emergence of resistant strains, and guide the development of targeted therapeutics. Predictive models that can forecast patterns of resistance will assist in the direction of proactive interventions at clinical and public health levels.

Progress in microbiome research is likely to accelerate through AI-enabled multi-omics integration. Combining genomics, proteomics, metabolomics, and metagenomics with advanced computational tools can uncover intricate host–microbe interactions and provide deeper insights into microbial ecosystems.

Quick diagnostics and pathogen identification signify another boundary. AI-driven diagnostic systems are expected to facilitate quicker and more precise pathogen identification, with instant data analysis enhancing the early identification and handling of infectious diseases.

Environmental microbiology and ecohealth uses are also promising. Predictive AI models can track microbial community dynamics in various ecosystems, assess the impacts of environmental change on biodiversity, and determine the implications for public health.

Laboratory automation in microbiology will further be improved through robotics driven by artificial intelligence, which has the capability to automate repetitive processes, minimize error rates, and speed up sample processing. AI-based automatic systems will also enhance laboratory efficiency and dependability.

Human–AI collaboration will continue to define microbiological research. AI will not replace scientists but instead act as an augmentation tool, helping with data analysis, hypothesis formulation, and experimental design. These decision-support systems can enable microbiologists to make more data-driven and accurate decisions.

Drug repurposing and combination treatment are other fields where AI could accelerate the progress. Algorithms can quickly uncover known drugs that possess unidentified antimicrobial properties, while predictive modeling of drug combinations can maximize therapeutic effectiveness while preventing resistance build-up.

Global health surveillance is expected to benefit substantially from AI-driven predictive systems. These tools can enable real-time monitoring of infectious disease outbreaks, facilitate rapid responses by public health authorities, and strengthen preparedness against emerging microbial threats.

Synthetic biology is set to be transformed through the incorporation of AI. Machine learning can aid in the systematic creation of engineered microbes for uses like bioremediation, bio-manufacturing, and therapeutic development. AI-driven precision engineering of microbial systems will unlock new possibilities in synthetic biology.

CONCLUSION

Artificial intelligence has moved very quickly as a revolutionary force in microbiology, closing the gap between old-fashioned experimental methods and high-performance computational analysis. From speeding microbial identification and antimicrobial resistance prediction to facilitating microbiome profiling, vaccine development, and outbreak detection, AI is redefining both the practice of laboratory science and clinical care. These breakthroughs hold the promise of faster diagnosis, precision therapeutics, and improved global readiness against infectious diseases.

REFERENCES

1. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nature medicine. 2019 Jan;25(1):44-56.
2. Camacho DM, Collins KM, Powers RK, Costello JC, Collins JJ. Next-generation machine learning for biological networks. Cell. 2018 Jun 14;173(7):1581-92.

3. Zou J, Huss M, Abid A, Mohammadi P, Torkamani A, Telenti A. A primer on deep learning in genomics. Nature genetics. 2019 Jan;51(1):12-8.
4. Stokes JM, Yang K, Swanson K, Jin W, Cubillos-Ruiz A, Donghia NM, MacNair CR, French S, Carfrae LA, Bloom-Ackermann Z, Tran VM. A deep learning approach to antibiotic discovery. Cell. 2020 Feb 20;180(4):688-702.
5. Kim JI, Maguire F, Tsang KK, Gouliouris T, Peacock SJ, McAllister TA, McArthur AG, Beiko RG. Machine learning for antimicrobial resistance prediction: current practice, limitations, and clinical perspective. Clinical microbiology reviews. 2022 Sep 21;35(3):e00179-21.
6. Weis CV, Jutzeler CR, Borgwardt K. Machine learning for microbial identification and antimicrobial susceptibility testing on MALDI-TOF mass spectra: a systematic review. Clinical Microbiology and Infection. 2020 Oct 1;26(10):1310-7.
7. Li M, Wang Y, Li F, Zhao Y, Liu M, Zhang S, Bin Y, Smith AI, Webb GI, Li J, Song J. A deep learning-based method for identification of bacteriophage-host interaction. IEEE/ACM transactions on computational biology and bioinformatics. 2020 Aug 19;18(5):1801-10.
8. Rawson TM, Peiffer-Smadja N, Holmes A. Artificial intelligence in infectious diseases. InArtificial Intelligence in Medicine 2021 Jul 11 (pp. 1-14). Cham: Springer International Publishing.
9. Esteva A, Robicquet A, Ramsundar B, Kuleshov V, DePristo M, Chou K, Cui C, Corrado G, Thrun S, Dean J. A guide to deep learning in healthcare. Nature medicine. 2019 Jan;25(1):24-9.
10. Alanazi A, Aldakhil L, Aldhoayan M, Aldosari B. Machine Learning for Early Prediction of Sepsis in Intensive Care Unit (ICU) Patients. Medicina (Kaunas). 2023 Jul 9;59(7):1276. doi: 10.3390/medicina59071276. PMID: 37512087; PMCID: PMC10385427.
11. Zhang X, Zhang D, Zhang X, Zhang X. Artificial intelligence applications in the diagnosis and treatment of bacterial infections. Front Microbiol. 2024 Aug 6;15:1449844. doi: 10.3389/fmicb.2024.1449844. PMID: 39165576; PMCID: PMC11334354.
12. Chen ML, Doddi A, Royer J, Freschi L, Schito M, Ezewudo M, Kohane IS, Beam A, Farhat M. Beyond multidrug resistance: Leveraging rare variants with machine and statistical learning models in Mycobacterium tuberculosis resistance prediction. EBioMedicine. 2019 May 1;43:356-69.
13. Zou J, Huss M, Abid A, Mohammadi P, Torkamani A, Telenti A. A primer on deep learning in genomics. Nature genetics. 2019 Jan;51(1):12-8.
14. Ardila CM, González-Arroyave D, Tobón S. Machine learning for predicting antimicrobial resistance in critical and high-priority pathogens: A systematic review considering antimicrobial susceptibility tests in real-world healthcare settings. Plos one. 2025 Feb 25;20(2):e0319460.
15. Su M, Satola SW, Read TD. Genome-based prediction of bacterial antibiotic resistance. Journal of clinical microbiology. 2019 Mar;57(3):10-128.
16. Nguyen M, Long SW, McDermott PF, Olsen RJ, Olson R, Stevens RL, Tyson GH, Zhao S, Davis JJ. Using machine learning to predict antimicrobial MICs and associated genomic features for nontyphoidal Salmonella. Journal of clinical microbiology. 2019 Feb;57(2):10-128.
17. Tharmakulasingam M. Interpretable machine learning models to predict antimicrobial resistance (Doctoral dissertation, University of Surrey).
18. Topçuoğlu BD, Lesniak NA, Ruffin IV MT, Wiens J, Schloss PD. A framework for effective application of machine learning to microbiome-based classification problems. MBio. 2020 Jun 30;11(3):10-128.
19. Quince C, Walker AW, Simpson JT, Loman NJ, Segata N. Shotgun metagenomics, from sampling to analysis. Nature biotechnology. 2017 Sep;35(9):833-44.
20. Marcos-Zambrano LJ, Karaduzovic-Hadziabdic K, Loncar Turukalo T, Przymus P, Trajkovik V, Aasmets O, Berland M, Gruca A, Hasic J, Hron K, Klammsteiner T, Kolev M, Lahti L, Lopes MB, Moreno V, Naskinova I, Org E, Paciência I, Papoutsoglou G, Shigdel R, Stres B, Vilne B, Yousef M, Zdravevski E, Tsamardinos I, Carrillo de Santa Pau E, Claesson MJ, Moreno-Indias I, Truu J. Applications of Machine Learning in Human Microbiome Studies: A Review on Feature Selection, Biomarker Identification, Disease Prediction and Treatment. Front Microbiol. 2021 Feb 19;12:634511. doi: 10.3389/fmicb.2021.634511. PMID: 33737920; PMCID: PMC7962872.
21. Angermueller C, Pärnamaa T, Parts L, Stegle O. Deep learning for computational biology. Molecular systems biology. 2016 Jul;12(7):878.
22. Zhang Y, Jiang H, Ye T, Juhas M. Deep learning for imaging and detection of microorganisms. Trends in Microbiology. 2021 Jul 1;29(7):569-72.
23. Zhu Q, Huo B, Sun H, Li B, Jiang X. Application of deep learning in microbiome. Journal of Artificial Intelligence for Medical Sciences. 2020 Jun;1(1):23-9.
24. Fiannaca A, La Paglia L, La Rosa M, Lo Bosco G, Renda G, Rizzo R, Gaglio S, Urso A. Deep learning models for bacteria taxonomic classification of metagenomic data. BMC bioinformatics. 2018 Jul 9;19(Suppl 7):198.
25. Franco-Duarte R, Černáková L, Kadam S, S. Kaushik K, Salehi B, Bevilacqua A, Corbo MR, Antolak H, Dybka-Stępień K, Leszczewicz M, Relison Tintino S. Advances in chemical and biological methods to identify microorganisms—from past to present. Microorganisms. 2019 May 13;7(5):130.
26. Sarker IH. Deep learning: a comprehensive overview on techniques, taxonomy, applications and research directions. SN computer science. 2021 Nov;2(6):1-20.
27. Smith KP, Kirby JE. Image analysis and artificial intelligence in infectious disease diagnostics. Clinical Microbiology and Infection. 2020 Oct 1;26(10):1318-23.
28. Chaturvedi N, Yadav MK, Sharma M. Applications of artificial intelligence and machine learning in microbial diagnostics and identification. InMethods in microbiology 2024 Jan 1 (Vol. 55, pp. 213-230). Academic Press.
29. Alsulimani A, Akhter N, Jameela F, Ashgar RI, Jawed A, Hassani MA, Dar SA. The impact of artificial intelligence on microbial diagnosis. Microorganisms. 2024 May 23;12(6):1051.
30. Grignaffini F, Simeoni P, Alisi A, Frezza F. Computer-aided diagnosis systems for automatic malaria parasite detection and classification: a systematic review. Electronics. 2024 Aug 11;13(16):3174.
31. Kumar S, Arif T, Alotaibi AS, Malik MB, Manhas J. Advances towards automatic detection and classification of parasites microscopic images using deep convolutional neural network: methods, models and research directions. Archives of Computational Methods in Engineering. 2023 Apr;30(3):2013-39.
32. Sakagianni A, Koufopoulou C, Feretzakis G, Kalles D, Verykios VS, Myrianthefs P. Using machine learning to predict antimicrobial resistance―a literature review. Antibiotics. 2023 Feb 24;12(3):452.
33. Li Y, Xu Z, Han W, Cao H, Umarov R, Yan A, Fan M, Chen H, Duarte CM, Li L, Ho PL. HMD-ARG: hierarchical multi-task deep learning for annotating antibiotic resistance genes. Microbiome. 2021 Feb 8;9(1):40.
34. MacDougall C, Polk RE. Antimicrobial stewardship programs in health care systems. Clinical microbiology reviews. 2005 Oct;18(4):638-56.
35. Rozera T, Pasolli E, Segata N, Ianiro G. Learning and Artificial Intelligence in the Multi-Omics Approach to Gut Microbiota. gut. 2025;3:Q4.
36. Li R. Using artificial intelligence (AI)-based computer vision methods to investigate associations between hand movement and Alzheimer's Disease (AD) risk (Doctoral dissertation, University of Tasmania).
37. Blanco-Míguez A, Beghini F, Cumbo F, McIver LJ, Thompson KN, Zolfo M, Manghi P, Dubois L, Huang KD, Thomas AM, Nickols WA. Extending and improving metagenomic taxonomic profiling with uncharacterized species using MetaPhlAn 4. Nature biotechnology. 2023 Nov;41(11):1633-44.
38. Rahman SZ, Senthil R, Ramalingam V, Gopal R. Predicting infectious disease outbreaks with machine learning and epidemiological data. Journal of Advanced Zoology. 2023 Nov 26;44(S4):110-21.

39. Villanueva-Miranda I, Xiao G, Xie Y. Artificial Intelligence in Early Warning Systems for Infectious Disease Surveillance: A Systematic Review. Frontiers in Public Health. 2025 Jun 23;13:1609615.
40. Wang HY, Hung CC, Chen CH, Lee TY, Huang KY, Ning HC, Lai NC, Tsai MH, Lu LC, Tseng YJ, Lu JJ. Increase Trichomonas vaginalis detection based on urine routine analysis through a machine learning approach. Scientific reports. 2019 Aug 19;9(1):11074.
41. Namba-Nzanguim CT, Turon G, Simoben CV, Tietjen I, Montaner LJ, Efange SM, Duran-Frigola M, Ntie-Kang F. Artificial intelligence for antiviral drug discovery in low resourced settings: A perspective. Frontiers in Drug Discovery. 2022 Nov 2;2:1013285.
42. Jamal S, Khubaib M, Gangwar R, Grover S, Grover A, Hasnain SE. Artificial Intelligence and Machine learning based prediction of resistant and susceptible mutations in Mycobacterium tuberculosis. Scientific reports. 2020 Mar 26;10(1):5487.
43. Franceschetti L, Lodetti G, Blandino A, Amadasi A, Bugelli V. Exploring the role of the human microbiome in forensic identification: opportunities and challenges. International Journal of Legal Medicine. 2024 Sep;138(5):1891-905.
44. Bonah E, Huang X, Aheto JH, Osae R. Application of hyperspectral imaging as a nondestructive technique for foodborne pathogen detection and characterization. Foodborne pathogens and disease. 2019 Oct 1;16(10):712-22.
45. Murgia L. Development of a new medical device for the diagnosis and management of Urinary Tract Infections (UTIs).
46. Sahu PS, Kumar S, Kumar N, Prakash VP. Total Laboratory Automation in Clinical Microbiology: A Note on Needs, Challenges, and Applications in a Pandemic Scenario. Applied Microbiology: Theory & Technology. 2024 Apr 1:64-71.
47. Bignami EG, Berdini M, Panizzi M, Domenichetti T, Bezzi F, Allai S, Damiano T, Bellini V. Artificial intelligence in sepsis management: an overview for clinicians. Journal of Clinical Medicine. 2025 Jan 6;14(1):286.
48. Yuan S, Yang Z, Li J, Wu C, Liu S. AI-Powered early warning systems for clinical deterioration significantly improve patient outcomes: a meta-analysis. BMC Medical Informatics and Decision Making. 2025 Jun 2;25(1):203.
49. van der Werff SD, van Rooden SM, Henriksson A, Behnke M, Aghdassi SJ, van Mourik MS, Nauclér P. The future of healthcare-associated infection surveillance: Automated surveillance and using the potential of artificial intelligence. Journal of Internal Medicine. 2025 Jun 9.
50. Lakhani P, Sundaram B. Deep learning at chest radiography: automated classification of pulmonary tuberculosis by using convolutional neural networks. Radiology. 2017 Aug;284(2):574-82.
51. Chaturvedi N, Yadav MK, Sharma M. Applications of artificial intelligence and machine learning in microbial diagnostics and identification. InMethods in microbiology 2024 Jan 1 (Vol. 55, pp. 213-230). Academic Press.
52. Talat A, Khan AU. Artificial intelligence as a smart approach to develop antimicrobial drug molecules: A paradigm to combat drug-resistant infections. Drug discovery today. 2023 Apr 1;28(4):103491.
53. Serafim MS, Kronenberger T, Oliveira PR, Poso A, Honorio KM, Mota BE, Maltarollo VG. The application of machine learning techniques to innovative antibacterial discovery and development. Expert Opinion on Drug Discovery. 2020 Oct 2;15(10):1165-80.
54. Gupta U, Pranav A, Kohli A, Ghosh S, Singh D. The contribution of artificial intelligence to drug discovery: Current progress and prospects for the future. Microbial data intelligence and computational techniques for sustainable computing. 2024 Mar 1:1-23.
55. Macesic N, Bear Don't Walk IV OJ, Pe'er I, Tatonetti NP, Peleg AY, Uhlemann AC. Predicting phenotypic polymyxin resistance in Klebsiella pneumoniae through machine learning analysis of genomic data. Msystems. 2020 Jun 30;5(3):10-128.
56. Ali H. AI for pandemic preparedness and infectious disease surveillance: predicting outbreaks, modeling transmission, and optimizing public health interventions. Int J Res Publ Rev. 2024 Aug;5(8):4605-19.
57. Adepoju DA, Adepoju AG. Establishing Ethical Frameworks for Scalable Data Engineering and Governance in AI-Driven Healthcare Systems.
58. Adeniran AA, Onebunne AP, William P. Explainable AI (XAI) in healthcare: Enhancing trust and transparency in critical decision-making. World Journal of Advanced Research and Reviews. 2024;23(3):2647-58.
59. Javed H, El-Sappagh S, Abuhmed T. Robustness in deep learning models for medical diagnostics: security and adversarial challenges towards robust AI applications. Artificial Intelligence Review. 2024 Nov 8;58(1):12.
60. Rahman MH, Hossan KM, Uddin MK, Hossain MD. Improving Collaborative Interactions Between Humans and Artificial Intelligence to Achieve Optimal Patient Outcomes in the Healthcare Industry. Available at SSRN 5029975. 2024 Sep 1.
61. McIntosh TR, Susnjak T, Liu T, Watters P, Xu D, Liu D, Halgamuge MN. From google gemini to openai q*(q-star): A survey on reshaping the generative artificial intelligence (ai) research landscape. Technologies. 2025 Jan 30;13(2):51.
62. Ashraf AA, Rai S, Alva S, Alva PD, Naresh S. Revolutionizing clinical laboratories: The impact of artificial intelligence in diagnostics and patient care. Diagnostic Microbiology and Infectious Disease. 2025 Apr 1;111(4):116728.
63. Pillay TS. Increasing the impact and value of laboratory medicine through effective and AI-assisted communication. EJIFCC. 2025 Feb 28;36(1):12.
64. Lopatkin AJ, Collins JJ. Predictive biology: modelling, understanding and harnessing microbial complexity. Nature Reviews Microbiology. 2020 Sep;18(9):507-20.
65. Raajaraam L, Raman K. Modeling microbial communities: perspective and challenges. ACS Synthetic Biology. 2024 Aug 16;13(8):2260-70.
66. Oliveira M, Antunes W, Mota S, Madureira-Carvalho Á, Dinis-Oliveira RJ, Dias da Silva D. An overview of the recent advances in antimicrobial resistance. Microorganisms. 2024 Sep 21;12(9):1920.
67. Alsulimani A, Akhter N, Jameela F, Ashgar RI, Jawed A, Hassani MA, Dar SA. The impact of artificial intelligence on microbial diagnosis. Microorganisms. 2024 May 23;12(6):1051.
68. Alkhatib R, Gaede KI. Data management in biobanking: strategies, challenges, and future directions. BioTech. 2024 Sep 2;13(3):34.
69. CHASSAIGNE H, PANIDIS D, REINA V, XYDEROU P, GRIESINGER C. Interrogating the research and development pipeline of artificial intelligence (AI) in health: diagnosis and prediction-based diagnosis.
70. Patra S. Unveiling the Synergy: Exploring Multidisciplinary Paradigms in Cutting-Edge Research.